International Reference Pricing in the Context of US Drug Policy

被引:5
|
作者
Frank, Richard [1 ]
Conti, Rena M. [2 ]
Gruber, Jonathan [3 ]
机构
[1] Harvard Univ, Cambridge, MA 02138 USA
[2] Boston Univ, Boston, MA USA
[3] MIT, Cambridge, MA USA
关键词
prescription drug prices; international reference prices; external reference prices;
D O I
10.1215/03616878-10041177
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
International reference prices (IRP), also called external reference prices, are widely used across developed nations. IRP uses the prices paid in other countries to either inform negotiations with the pharmaceutical industry or as a cap on market prices. The authors review the application of IRP to cap the prices of negotiated out-comes in the context of US proposals for changing the way prescription drug prices are established for the Medicare program. They examine the economic, political, and administrative issues associated with the use of IRP, and they summarize the evidence on the impacts of IRP.
引用
收藏
页码:779 / 796
页数:18
相关论文
共 50 条
  • [31] Discuss 'Context' Matters in Comparative and International Research in Education with Reference to the Dilemmas of Policy Transfer
    Zhang, Li-Na
    Zhao, Rui
    2018 3RD ANNUAL INTERNATIONAL CONFERENCE ON EDUCATION SCIENCE AND EDUCATION MANAGEMENT (ESEM 2018), 2018, : 87 - 92
  • [32] Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe
    Vokinger, Kerstin N.
    Hwang, Thomas J.
    Daniore, Paola
    Lee, ChangWon C.
    Tibau, Ariadna
    Grischott, Thomas
    Rosemann, Thomas J.
    Kesselheim, Aaron S.
    JAMA ONCOLOGY, 2021, 7 (09)
  • [33] Therapeutic reference pricing and drug innovation incentives?
    Straume, Odd Rune
    ECONOMICS LETTERS, 2023, 222
  • [34] Association of Reference Pricing with Drug Selection and Spending
    Robinson, James C.
    Whaley, Christopher M.
    Brown, Timothy T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (07): : 658 - 665
  • [35] Reference Pricing: An Effective Model for the US Pharmaceutical Industry?
    Salter, Marie
    NORTHWESTERN JOURNAL OF INTERNATIONAL LAW & BUSINESS, 2015, 35 (02): : 413 - 438
  • [36] Reference pricing for drugs: Is it compatible with US health care?
    Kanavos, P
    Reinhardt, U
    HEALTH AFFAIRS, 2003, 22 (03) : 16 - 30
  • [37] Inflation Reduction Act and US drug pricing
    Sarpatwari, Ameet
    BMJ-BRITISH MEDICAL JOURNAL, 2022, 378
  • [38] On the welfare analysis of external reference pricing and reimbursement policy
    Dong, Van-Chung
    Lin, Yan-Shu
    Shih, Pei-Cyuan
    ESTUDIOS DE ECONOMIA, 2023, 50 (01): : 133 - 158
  • [39] The Optimal Control Policy of Dynamic Pricing with Reference Effect
    Yang, Hui
    Jin, Hui
    PROCEEDINGS OF THE 2015 INTERNATIONAL CONFERENCE ON TEST, MEASUREMENT AND COMPUTATIONAL METHODS (TMCM 2015), 2015, 26 : 137 - 140
  • [40] Tying Medicare Part B Drug Prices to International Reference Pricing Will Devastate R&D
    Duane Schulthess
    Daniel Gassull
    Steven Maisel
    Therapeutic Innovation & Regulatory Science, 2019, 53 : 746 - 751